Mavoglurant
Chemical compound
From Wikipedia, the free encyclopedia
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions.[1][2] It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5).[3][4][5]
| |
| Names | |
|---|---|
| Preferred IUPAC name
Methyl (3aR,4S,7aR)-4-hydroxy-4-[(3-methylphenyl)ethynyl]octahydro-1H-indole-1-carboxylate | |
| Other names
AFQ056 | |
| Identifiers | |
3D model (JSmol) |
|
| ChemSpider | |
| ECHA InfoCard | 100.219.728 |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C19H23NO3 | |
| Molar mass | 313.397 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Mavoglurant was under development by Novartis and reached phase II and phase III clinical trials.[2][6] Phase IIb/III dose finding and evaluation trials for fragile X-syndrome were discontinued by the end of 2014.[7] Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.[8] Mavoglurant was also in phase II clinical trials for Levodopa-induced dyskinesia.[9][10] In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now.[11] Novartis was conducting a clinical trial with this drug on obsessive–compulsive disorder.[12]
Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results.[7] Development was discontinued for other indications by 2017.[1]
Recently, Stalicla, a biotech company applying artificial intelligence to identify subgroups of high-responder patients, acquired worldwide rights from Novartis to progress the drug for substance-use and neurodevelopmental disorders.[13][14][15]
